Roivant Sciences ROIV Ratios & Valuation
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Free cash flow margin | -9,183.5%-6,278pp | -5,761.5%-3,206pp | -3,858.4%-1,750pp | -3,695.9%-1,735pp | -2,905.2%-1,367pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 18.4×-15.1× | 30.7×-7.2× | 33.7×+23.3× | 40.5×+12.6× | 33.5×+8.2× | |
| Quick ratio | 18.4×-15.1× | 30.7×-7.2× | 33.7×+23.3× | 40.5×+12.8× | 33.5×+8.4× | |
| Cash ratio | 5×+4.4× | 0.6×-0.1× | 0.8×+0.5× | 0.8×-25.6× | 0.6×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Per Share | ||||||
| Book value per share | $6.52+1.0% | $6.13-14.7% | $6.41-8.6% | $6.39-8.1% | $6.46-10.0% | |
| Valuation | ||||||
| Market capitalization | $19.82B+175% | $15.09B+75.3% | $10.33B+21.7% | $7.84B+0.9% | $7.2B-14.9% | |
| Enterprise value | $18.51B+157% | $15.11B+75.4% | $10.33B+22.7% | $7.85B+219% | $7.21B-17.9% | |
| Price / sales | 2,400.1×+2,152× | 1,133.9×+852× | 508.2×+279× | 337.7×+123× | 247.8×+78.1× | |
| Price / book | 4.4×+2.8× | 3.5×+1.9× | 2.4×+0.7× | 1.8×+0.4× | 1.5×+0.1× | |
| EV / sales | 2,241.3×+1,993× | 1,135.2×+853× | 508.1×+281× | 337.9×+270× | 248×+71.9× | |
| Free cash flow yield | -3.8%+7.9pp | -5.1%+4.0pp | -7.6%+1.6pp | -10.9%-1.8pp | -11.7%-2.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Roivant Sciences's ratios come from?
- Every ratio is computed from Roivant Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
